Euflexxa 1% sodium hyaluronate - Synovial fluid supplementation substance
Access comprehensive regulatory information for Euflexxa 1% sodium hyaluronate - Synovial fluid supplementation substance in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Ferring Pharmaceuticals Pty Ltd, manufactured by Bio-Technology General (Israel) Ltd in Israel. The device registration started on May 05, 2015.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.
EUFLEXXA is indicated for the treatment of pain caused by osteoarthritis of the knee joint or other synovial joints. EUFLEXXA aids in lubrication of the joint, allows for greater mobility and flexibility of the treated joint, and reduces pain in the affected joint.